Oral Wegovy approved
The FDA has approved an oral form of Wegovy, meaning the GLP‑1 therapy widely used as an injection is now available as a pill—an important accessibility shift for people who avoid injections (appliedclinicaltrialsonline.com). Approval followed positive Phase III OASIS 4 results, and Novo Nordisk signaled it planned a full U.S. launch with manufacturing already underway in North Carolina after an early‑January 2026 roll‑out plan (appliedclinicaltrialsonline.com).
Weight-loss drugs that started as weekly shots are now crossing into a different category: on December 23, 2025, the Food and Drug Administration approved Wegovy tablets, giving semaglutide a pill form for obesity treatment in adults. (fda.gov) Semaglutide works by copying a gut hormone called glucagon-like peptide-1, which is one of the body’s “I’m full” signals after eating. In Wegovy, that signal is used to reduce appetite and support long-term weight loss alongside diet and physical activity. (wegovy.com) Getting that kind of medicine into a tablet has been unusually hard because protein-like drugs are usually broken down in the stomach before they can do much. Novo Nordisk had already turned semaglutide into an oral diabetes drug called Rybelsus, and Wegovy tablets extend that same idea into obesity care at a higher 25 milligram daily dose. (novonordisk.mediaroom.com) The approval rested on a Phase 3 study called OASIS 4, which followed 307 adults for 64 weeks. People taking oral semaglutide 25 milligrams lost an average of 16.6% of body weight, versus 3.6% on placebo, in results published in The New England Journal of Medicine on September 17, 2025. (acc.org) That trial enrolled adults with obesity, or adults with overweight plus at least one weight-related condition, and it excluded people with diabetes. The design mattered because it tested the pill in the same broad weight-management population that made injectable Wegovy a blockbuster. (biospace.com) The tablet is not a simple swap for the shot in day-to-day use. The prescribing information says oral Wegovy must be taken once each morning on an empty stomach with no more than 4 ounces of plain water, and patients must wait at least 30 minutes before eating, drinking, or taking other oral medicines. (fda.gov) The safety picture looks familiar because it is the same active drug. The label carries a boxed warning about thyroid C-cell tumors seen in rodents, and common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, and indigestion. (novo-pi.com) The approval also gives the pill a cardiovascular claim, not just a weight-loss claim. The label says Wegovy tablets can be used to reduce the risk of major cardiovascular events such as cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease and obesity or overweight. (fda.gov) Novo Nordisk said in late 2025 that a full United States launch was planned for early January 2026, with manufacturing already underway in North Carolina. By April 2026, the company was already promoting new comparison data against Eli Lilly’s oral candidate orforglipron, which shows how fast the race has shifted from “Can these drugs work as pills?” to “Which pill works best?” (appliedclinicaltrialsonline.com) (novonordisk.com) The bigger change is practical, not scientific: Wegovy is no longer only a refrigerator-and-needle product. For patients who delay treatment because they do not want injections, the Food and Drug Administration has now opened a second door. (prnewswire.com)
